Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

Abstract:

:Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-to-day variability in glucose-lowering effect than the long-acting insulin analogue insulin glargine. In clinical trials, insulin degludec achieved similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower risk of nocturnal hypoglycaemia. In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety. A 200 U/mL formulation of insulin degludec is also available for use in patients who require large volumes of basal insulin. Insulin degludec/insulin aspart was noninferior to the long-acting insulin analogue insulin detemir in patients with type 1 diabetes and has the potential to reduce the number of daily injections. Trial results also indicate that insulin degludec/insulin aspart may be an appropriate option for initiating insulin therapy in patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs. Subcutaneous insulin degludec was generally well tolerated in patients with type 1 or 2 diabetes. In conclusion, insulin degludec and insulin degludec/insulin aspart represent a useful advance in the treatment of type 1 or 2 diabetes.

journal_name

Drugs

journal_title

Drugs

authors

Keating GM

doi

10.1007/s40265-013-0051-1

subject

Has Abstract

pub_date

2013-05-01 00:00:00

pages

575-93

issue

6

eissn

0012-6667

issn

1179-1950

journal_volume

73

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Peramivir: A Review in Uncomplicated Influenza.

    abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0981-8

    authors: Scott LJ

    更新日期:2018-09-01 00:00:00

  • Atenolol with and without nifedipine in the treatment of angina pectoris. Preliminary report.

    abstract::Atenolol and nifedipine have been shown to be effective single agents in angina pectoris, but reports suggest that additional benefits may be conferred by combining the 2 drugs. Therefore, to establish that the combination regimen was at least as effective as either atenolol or nifedipine alone, a multicentre study wa...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800354-00012

    authors: Sandberg M,Foale RA

    更新日期:1988-01-01 00:00:00

  • Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

    abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0489-4

    authors: Trendowski M

    更新日期:2015-11-01 00:00:00

  • Dexamethasone in adults with community-acquired bacterial meningitis.

    abstract::Bacterial meningitis in adults is a severe disease with high fatality and morbidity rates. Experimental studies have shown that the inflammatory response in the subarachnoid space is associated with an unfavourable outcome. In these experiments, corticosteroids, and in particular dexamethasone, were able to reduce the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666040-00002

    authors: van de Beek D,de Gans J

    更新日期:2006-01-01 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

    abstract::Amorolfine is a structurally unique, topically active antifungal agent, which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in vitro activity includes dermatophyte, dimorphic, some dematiaceous and filamentous fungi, and some yeasts. In clinical trials, application of amorolfine 5% nail ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549010-00008

    authors: Haria M,Bryson HM

    更新日期:1995-01-01 00:00:00

  • Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

    abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363200-00008

    authors: Keating G,Figgitt D

    更新日期:2003-01-01 00:00:00

  • Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumatoid arthritis following tiaprofenic acid or indomethacin treatment.

    abstract::Prostaglandin E2 (PGE2) is a potent stimulator of inflammation, and the inhibition of its synthesis is one possible mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). We have investigated patients suffering from rheumatoid arthritis to determine how synovial fluid levels of PGE2 are affected by tia...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800351-00004

    authors: Daymond TJ,Rowell FJ

    更新日期:1988-01-01 00:00:00

  • Myocardial infarction. Secondary prevention with nifedipine.

    abstract::The rationale for the use of nifedipine in patients with acute myocardial infarction (MI) is based on the various cardiovascular actions of the compound: reduction of myocardial oxygen consumption by attenuation of cardiac and vascular smooth muscle tension; augmentation of oxygen and substrate supply after increased ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.2165/00003495-199100422-00007

    authors: Rafflenbeul W,Ebner F

    更新日期:1991-01-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • Rational use of disease-modifying antirheumatic drugs.

    abstract::The currently available, most frequently used disease-modifying antirheumatic drugs (DMARDs) include auranofin, azathioprine, D-penicillamine, gold sodium thiomalate, hydroxychloroquine, methotrexate (amethopterin) and sulphasalazine. Controlled trials of these agents are reviewed to compare their relative efficacy an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199039010-00003

    authors: Furst DE

    更新日期:1990-01-01 00:00:00

  • Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.

    abstract::Although venous thromboembolism has occasionally been reported after hospital discharge in patients who have undergone total hip replacement (THR), this risk has not been fully quantified and the usefulness of a prophylactic treatment has not been evaluated. We conducted a single-centre prospective randomised double-b...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199600527-00009

    authors: Planes A,Vochelle N,Darmon JY,Fagola M,Bellaud M,Compan D,Saliba E,Weisslinger N,Huet Y

    更新日期:1996-01-01 00:00:00

  • Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.

    abstract::Many drugs alter the anticoagulant effect of oral coumarins. It is essential that physicians be aware of interactions leading to increased or decreased anticoagulation or to erratic control. Interacting drugs can be classified as influencing the pharmacodynamics (pharmacological actions) or the pharmacokinetics (absor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611060-00006

    authors: MacLeod SM,Sellers EM

    更新日期:1976-01-01 00:00:00

  • Pharmacokinetics of ofloxacin in patients on haemodialysis treatment.

    abstract::Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After severa...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700341-00014

    authors: Dörfler A,Schulz W,Burkhardt F,Zichner M

    更新日期:1987-01-01 00:00:00

  • Correction to: Deprescribing Opioids in Chronic Non‑cancer Pain: Systematic Review of Randomised Trials.

    abstract::Page 9, Fig. 2, which originally appeared as. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01416-7

    authors: Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

    更新日期:2020-10-01 00:00:00

  • Coronary thrombolysis for evolving myocardial infarction.

    abstract::An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428050-00004

    authors: Spann JF,Sherry S

    更新日期:1984-11-01 00:00:00

  • Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

    abstract::Trifluridine (trifluorothymidine) is an antiviral agent for topical use in the eye, and is structurally related to idoxuridine. In vitro studies have shown that it effectively inhibits the replication of herpes simplex virus type 1, which causes primary keratoconjunctivitis and recurrent epithelial keratitis in man. I...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198223050-00001

    authors: Carmine AA,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1982-05-01 00:00:00

  • Elbasvir/Grazoprevir: First Global Approval.

    abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0558-3

    authors: Keating GM

    更新日期:2016-04-01 00:00:00

  • The funny current: cellular basis for the control of heart rate.

    abstract::The 'funny' (pacemaker, I(f)) current, first described almost 30 years ago in sinoatrial node (SAN) myocytes, is a mixed sodium/potassium inward current, activated on hyperpolarisation in the diastolic range of voltages. 'Funny' (f) channels are activated by intracellular cyclic adenosine monophosphate (cAMP) concentr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767002-00003

    authors: DiFrancesco D,Borer JS

    更新日期:2007-01-01 00:00:00

  • Prevention of transplant rejection: current treatment guidelines and future developments.

    abstract::In the past 2 decades, progressive improvements in the results of organ transplantation as a therapeutic strategy for patients with end-stage organ disease have been achieved due to greater insight into the immunobiology of graft rejection and better measures for surgical and medical management. It is now known that T...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754040-00003

    authors: Perico N,Remuzzi G

    更新日期:1997-10-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

    abstract::Developments in drug delivery technology have expanded the formulations of 5-aminosalicylic acid (5-ASA) available to clinicians over the last 50 years. Delivery of adequate doses of 5-ASA to the colon can be achieved by pH-dependent, delayed-release or pro-drug formulations. Despite some variations in the pharmacokin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868080-00006

    authors: Fernandez-Becker NQ,Moss AC

    更新日期:2008-01-01 00:00:00

  • Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.

    abstract::Delamanid (Deltyba(®)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0331-4

    authors: Blair HA,Scott LJ

    更新日期:2015-01-01 00:00:00

  • Voriconazole : a review of its use in the management of invasive fungal infections.

    abstract::Voriconazole (VFEND), a synthetic second-generation, broad-spectrum triazole derivative of fluconazole, inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth. In the US, intravenous and/or oral voriconazole is recommended in adul...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767020-00009

    authors: Scott LJ,Simpson D

    更新日期:2007-01-01 00:00:00

  • Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

    abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00010

    authors: Markham A,Brogden RN

    更新日期:1995-06-01 00:00:00

  • Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates.

    abstract::Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01360-6

    authors: Kichler A,Jang S

    更新日期:2020-08-01 00:00:00

  • Cryptococcal infections: changing epidemiology and implications for therapy.

    abstract::Although the incidence of HIV-associated cryptococcosis has decreased in developed countries since the introduction of antiretroviral therapy, this disease continues to cause significant morbidity and mortality in sub-Saharan Africa among patients with AIDS. Important strides have been made in an attempt to decrease t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0037-z

    authors: La Hoz RM,Pappas PG

    更新日期:2013-05-01 00:00:00

  • Vitamin A acid: a review of its pharmacological properties and therapeutic use in the topical treatment of acne vulgaris.

    abstract::Vitamin A acid (retinoic acid: tretinoin) is a vitamin A derivative used in the topical treatment of acne. It acts by 'unseating' comedones, improvement developing slowly over a period of 2 to 3 or more months, and is also said to prevent the formation of new lesions. About three-quarters of patients with acne vulgari...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714060-00001

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-12-01 00:00:00

  • Grapefruit-drug interactions.

    abstract::Grapefruit juice and grapefruit product consumption have potential health benefits; however, their intake is also associated with interactions with certain drugs, including calcium channel blockers, immunosuppressants and antihistamines. The primary mechanism through which interactions are mediated is mechanism-based ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585250-000000000-00000

    authors: Seden K,Dickinson L,Khoo S,Back D

    更新日期:2010-12-24 00:00:00

  • Use of economic evaluation in decision making: evidence and recommendations for improvement.

    abstract::Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a num...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11538120-000000000-00000

    authors: Simoens S

    更新日期:2010-10-22 00:00:00